Physical AI, Embodied Intelligence, Neuromorphic Computing, and the Industrial Future of Intelligent Machines The Dream That Escaped the Dream The next revolution in artificial intelligence will be measured by what intelligence can accomplish in the physical world. After years of extraordinary progress in language models, software agents, computer vision, and computational reasoning, a more consequential […]
Author: Jay Berube
Run the Company Like a Relay
Speed is visible. The handoff decides the race. By Jay BerubeFounder & CEO, Berube BioVentures Run a company like a relay. Speed matters, but most races are lost in the handoff. I spent years running competitively, long enough to understand the difference between moving fast and racing well. My track PRs were 1:56.57 for 800 […]
Seduction Crushes Sales
Every Question Is a Tax—and Most Companies Ask Too Many Before They’ve Earned the Right One of the strangest things I have learned from building a large biotech funnel is that companies often say they want more business right up until more business actually arrives. Then something subtle happens. Instead of moving faster, they become […]
Give the Future More Future
Leadership, Becoming, and the Architecture of What Comes Next There is a peculiar violence in being seen too early. Someone encounters you at one moment in your life and believes they have encountered the whole. They see the company before the infrastructure exists, the scientist before the discovery, the founder before the network, the apprentice […]
The Open Ecosystem
Why Biotechnology Advances Through Structured Non-Closure Companies, organisms, infrastructure, capital, data, and the passages through which scientific possibility becomes medicine The Molecule Leaves the Laboratory A biotechnology program begins by looking smaller than it really is. A sequence appears on a screen. A protein binds. A microbial strain expresses something useful. An engineered cell changes […]
From Data to Direction: The New Intelligence Layer of Biotechnology
I. The Industry Has More Data Than Vision Biotechnology has become extraordinarily good at seeing the small. It can sequence a tumor, profile a transcriptome, quantify protein expression, monitor oxygen transfer, measure immune activation, model binding affinity, and predict structure at a level of resolution that would have seemed impossible a generation ago. It can […]
The Fire Horse Imperative: China, Structured Momentum, and the Architecture of Reliable Growth
In the cadence of the Chinese calendar, 2026 marks the arrival of the Year of the Fire Horse — a rare alignment that emerges only once every sixty years. Fire signifies acceleration and transformation: decisive force applied with consequence. It illuminates pressure points, compresses timelines, and converts latent potential into forward movement. The Horse represents […]
The Trust Layer: Why 2026 Rewards Platforms, Not Point Solutions
2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]
Why 2026 Is the Year Systems Beat Stories
(A note on: biotech, techbio, food tech, and the new operating physics of “real companies”) Every cycle reaches a point where narrative stops clearing the bar. The change is not theatrical. It shows up as a shift in diligence questions—questions that are operational, specific, and hard to bluff. When the questions change, the valuation framework […]
Biotech in 2026: The Real Bottlenecks in Scale-Up, Manufacturing, Capital, and Regulation
Where Biotech Actually Fails: Scale Is Not an Extension of the Lab Biotech still tells itself that scale is a later problem. In biotech in 2026, that belief is no longer naive — it is actively dangerous. The lab works.The data looks good.The organism behaves.The molecule binds.The titer hits the slide. And somewhere between that […]